Relationship between cytochrome P450 2C19 17 genotype distribution, platelet aggregation and bleeding risk in patients with blood stasis syndrome of coronary artery disease treated with clopidogrel

Journal of Chinese Integrative Medicine

Volumn 10, Issue 6, 2012, Pages 647-654

  Dai, Ze long ^a   Chen, Hui ^a   Wu, Xiao ying ^a  

^a FUJIAN MEDICAL UNIVERSITY   (China)

Author keywords

Bleeding; Blood stasis; Cytochrome p 450 enzyme system; Platelet aggregation inhabitors

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; CYTOCHROME; CYTOCHROME P450 2C19 17; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CORONARY ARTERY DISEASE; DRUG RESPONSE; FEMALE; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; RISK; THROMBOCYTE AGGREGATION; TREATMENT DURATION;

AGED; ARYL HYDROCARBON HYDROXYLASES; CORONARY ARTERY DISEASE; FEMALE; GENOTYPE; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION; TICLOPIDINE;

EID: 84863087029     PISSN: 16721977     EISSN: None     Source Type: Journal    
DOI: 10.3736/jcim20120608     Document Type: Article

References (15)

1. Du JP, Shi DZ, Li TC, Xu H, Chen H. Correlation between blood stasis syndrome and pathological characteristics of coronary artery in patients with coronary heart disease. J Chin Integr Med. 2010; 8 (9): 848-852. Chinese with abstract in English. Chinese source
2. Xu H, Lu XY, Chen KJ, Shi DZ. Study on correlation of blood-stasis syndrome and its accompanied syndromes with pathological changes showed in coronary angiography and restenosis after percutaneous coronary intervention. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2007; 27(1): 8-13. Chinese with abstract in English. Chinese source
3. Chen H, Zhang Y, Wu XY, Sun H. Investigation of upper gastrointestinal hemorrhage induced by enteric-coated aspirin in treating coronary heart disease. Zhonghua Lin Chuang Yi Shi Za Zhi Dian Zi Ban. 2010; 4(8): 1277-1281. Chinese with abstract in English. Chinese source
4. Sim SC, Risinger C, Dahl ML, Aklillu E, Christensen M, Bertilsson L, Ingelman-Sundberg M. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther. 2006; 79(1): 103-113.
5. Mendis S, Thygesen K, Kuulasmaa K, Giampaoli S, Mähönen M, Ngu Blackett K, Lisheng L; Writing group on behalf of the participating experts of the WHO consultation for revision of WHO definition of myocardial infarction. World Health Organization definition of myocardial infarction: 2008-09 revision. Int J Epidemiol. 2011; 40 (1): 139-146.
6. Weng WL. Recent research progress of blood stasis syndrome: the proceedings of the Second National Academic Conference on Blood Stasis Syndrome Research. Zhongguo Zhong Xi Yi Jie He Za Zhi. 1987; 7(3): 190-191. Chinese source.
7. Angiolillo DJ, Shoemaker SB, Desai B, Yuan H, Charlton RK, Bernardo E, Zenni MM, Guzman LA, Bass TA, Costa MA. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study. Circulation. 2007; 115(6): 708-716.
8. Chesebro JH, Knatterud G, Roberts R, Borer J, Cohen LS, Dalen J, Dodge HT, Francis CK, Hillis D, Ludbrook P, Markis JE, Mueller H, Passamani ER, Powers ER, Rao AK, Robertson T, Ross A, Ryan TJ, Sobel BE, Willerson J, Williams DO, Zaret BL, Braunwald E. Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation. 1987; 76(1): 142-154.
9. Desta Z, Zhao X, Shin JG, Flockhart DA. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet. 2002; 41(12): 913-958.
10. Savi P, Herbert JM. Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis. Semin Thromb Hemost. 2005; 31(2): 174-183.
11. Geiger J, Brich J, Hönig-Liedl P, Eigenthaler M, Schanzenbächer P, Herbert JM, Walter U. Specific impairment of human platelet P2Y(AC) ADP receptor-mediated signaling by the antiplatelet drug clopidogrel. Arterioscler Thromb Vase Biol. 1999; 19(8): 2007-2011.
12. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Alfonso F, Macaya C, Bass TA, Costa MA. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol. 2007; 49(14): 1505-1516.
13. Sibbing D, Koch W, Gebhard D, Schuster T, Braun S, Stegherr J, Morath T, Schmig A, von Beckerath N, Kastrati A. Cytochrome 2Cl9*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation. 2010; 121(4): 512-518.
14. Serebruany VL, Steinhubl SR, Berger PB, Malinin AI, Baggish JS, Bhatt DL, Topol EJ. Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials. Am J Cardiol. 2005; 95(10): 1218-1222.
15. Gurbel PA, Tantry US, Shuldiner AR, Kereiakes DJ. Genotyping: one piece of the puzzle to personalize antiplatelet therapy. J Am Coll Cardiol. 2010; 56(2): 112-116.